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Serum paraoxonase-1 (PON1) is a member of the paraoxonases family (PON1, PON2, and PON3). PON1 is synthesized and
secreted by the liver, and in circulation it is associated with HDL. PON1 has antioxidative properties, which are associated
with the enzyme’s capability to decrease oxidative stress in atherosclerotic lesions and to attenuate atherosclerosis development.
Epidemiological evidence demonstrates that low PON1 activity is associated with increased risk of cardiovascular events and
cardiovascular disease and is an independent risk factor for coronary artery disease. Therefore, pharmacological modulation of
PON1 activity or PON1 gene expression could constitute a useful approach for preventing atherosclerosis. A primary determinant
of serum PON1 levels is the availability of the enzyme for release by the liver, the principal site of PON1 production. Together with
the enzyme secretion rate, enzymatic turnover, and protein stability, the level of PON1 gene expression is a major determinant of
PON1 status. This paper summarizes recent progress in understanding the regulation of PON1 expression in hepatocytes.
1.Introduction
The atherosclerotic lesion is dominated by accumulation
of lipid peroxides along with the progression of early
plaque development [1]. Serum paraoxonase-1 (PON1) is
an HDL-associated lipolactonase, which is synthesized and
secreted by the liver [2]. PON1 has antioxidative properties,
which are associated with the enzyme’s capability to protect
LDL [3], as well as HDL [4] from oxidation, to decrease
macrophage oxidative status [5], to stimulate cholesterol
eﬄux from macrophages [6], to decrease oxidative status in
atherosclerotic lesions [7], and to attenuate atherosclerosis
development. Immunohistochemical analysis has revealed
accumulation of PON1 in the human atherosclerotic lesion
as it progresses from fatty streak to advanced lesion [8].
Recently it was demonstrated that PON1 acts to reduce the
oxidizing potency of lipids in atherosclerotic lesions, thus
providing protection against oxidation [9]. Epidemiological
evidence demonstrates that low PON1 activity is associated
with increased risk of cardiovascular events [10] and is an
independent risk factor for cardiovascular disease [11].
A variety of nongenetic factors have been shown to in-
ﬂuence serum PON1 levels and activity. PON1 under-
goes inactivation under oxidative stress and its activity
is preserved by dietary antioxidants [12]. Moderate daily
consumption of alcohol [13], vitamin C and E [14], wine
[15], or pomegranate juice [16], increased serum levels of
PON1 in animals and in humans. The level of PON1 in
serum is determined mainly by the status of PON1 gene
expression in the liver. However, the molecular mechanisms
involved in the regulation of hepatic PON1 gene expression
were less explored. This paper focuses on nongenetic factors
that inﬂuence PON1 gene expression in hepatocytes, reveal-
ing thus the molecular regulatory mechanisms modulating
hepatic PON1 gene expression.
2. PON1 GeneStructure
The paraoxonase (PON) gene family consists of three mem-
bers, PON1, PON2, and PON3, aligned next to each other
on chromosome 7 in human and on chromosome 6 in2 Journal of Lipids
the mouse [17]. In both species the three PONs contain
nine exons of approximately the same length. The human
PON1 and PON2 genes both have eight introns, and the
exon/intron junctions occur at equivalent positions. All
PON1s have an extracodon at position 106 (lysine in
human PON1). The approximate length of the human
PON1 is about 27kb. In previous studies, Deakin et al.
identiﬁed a single nucleotide polymorphism (SNP) in the
proximal region of the PON1 promoter (C-107T) with an
important impact on serum concentrations and activities of
the enzyme in diﬀerent populations [18]. A role for Sp1 and
sterol regulatory element-binding protein-2 (SREBP-2) was
proposed. A number of potential sterol regulatory element
(SRE) sequences exist within the proximal PON1 promoter
region that has been shown to be suﬃcient to respond to
statin treatment. The data designate the region around the
C-107T polymorphism as being the focus for transcription
factor actions and suggest a synergistic eﬀect of Sp1 and
SREBP-2 on promoter activity.
3. Inﬂammation
The liver plays a central role in the host response to
inﬂammation, which is associated with a wide array of
metabolic changes. These metabolic changes can be induced
by the administration of endotoxin (LPS) and by cytokines
which mediate the acute phase response, such as TNF and
IL-1. LPS and inﬂammatory cytokines induce composition
changes in HDL, due to alterations in hepatic mRNA levels
for HDL-related proteins. Administration of LPS and of
cytokines in Syrian hamsters resulted in a rapid and marked
reduction in PON1 mRNA in the liver, which was sustained
aslongas48hours[19]implicatingPON1asanegativeacute
phase protein. PON1 was also a negative, acute phase gene in
male mice. Within 24 hours of LPS administration, PON-1
mRNA level was reduced by 50% in male mice and increased
moderately in female mice, thus showing to be gender
dependent. Anti-inﬂammatory dexamethasone enhanced
PON-1mRNAlevelby2-foldinmaleandfemaleLPS-treated
mice and increased PON-1 expression by 8-fold in Hepa cell,
a mouse hepatoma cell line [20]. PON1 mRNA expression
in hepatocytes was reduced also by oxidized phospholipids
found in mildly oxidized LDL through the inﬂammatory
cytokine IL-6, and IL-6 alone produced the same pattern
of PON1 mRNA changes [21]. Liver damage induced by
CCl4 resulted in decreased PON1 gene transcription but
increased hepatic PON1 concentration that was related to
inhibited protein degradation [22]. Decreased PON1 gene
transcription was associated with PPARδ expression. These
changes were accompanied by increased hepatic MCP-1
concentration and gene expression, suggesting that PON1
has a hepatoprotective role against inﬂammation, ﬁbrosis,
and liver disease mediated by MCP-1. The interrelationships
between PON1 and MCP-1 in the regulation of hepatic
inﬂammation were recently reviewed by Camps et al., [23].
Proinﬂammatorycytokines,includingtumornecrosisfactor-
(TNF-)α, interleukin-1β, and interleukin-6 decreased the
expression of PON-1 and of apoA-I in hepatocytes by
inhibiting PPARα activation [24] and coordinately increased
the expression of serum Amyloid A (SAA) via nuclear factor
κB( N F - κB) in a manner dependent on both these key
transcriptional mediators.
4. Oxidation
The atherosclerotic lesion is dominated by accumulation
of lipid peroxides along with the progression of early
plaque development [25]. Oxidative stress is implicated in
atherosclerosis and cardiovascular diseases. Recent lines of
evidence appear to support the notion that serum PON1
undergoes inactivation under oxidative stress [12, 26–32].
However, the status of PON1 in the liver and its response
to oxidative stress were very poorly investigated. Lipid per-
oxidation induced by iron-ascorbate decreased PON1 pro-
tein in hepatic microsomes derived from humans and rats
[33], and this eﬀect was attributable to oxidative stress,
because the addition of the BHT antioxidant simultaneously
preventedtheoccurrenceoflipidperoxidationandimproved
the level of PON1 protein.
5. HypolipidemicDrugs
Probucol, a cholesterol-lowering drug with strong antiox-
idative property, signiﬁcantly increased serum PON1 con-
centration and upregulated PON1 mRNA expression in
hepatocytes of hypercholesterolemic rabbits [34].
Thus, PON1 gene transcription is modulated by var-
ious factors related to inﬂammation, oxidative stress, or
cholesterol. However, the mechanisms of regulation of
PON1 gene expression itself remained elusive. Recent studies
investigated the molecular mechanisms regulating PON1
gene expression. By comparing the eﬀects of fenoﬁbrate
to those statins on PON1 gene expression in hepatocytes,
Gou´ edard et al. characterized the promoter region of the
PON1 gene and identiﬁed at least one inducer and one
class of repressors of the PON1 gene [35]. They have shown
that ﬁbrates induced PON1 gene expression and this eﬀect
was repressed by PPARα activation, whereas statins inhibited
PON1 gene expression via antagonizing the liver X receptor
(LXR). On the contrary, Deakin et al. [36] demonstrated
that simvastatin upregulated dose-dependently PON1 gene
promoter activity, via increasing the nuclear factor sterol
regulatory element-binding protein-2 (SREBP-2), which is
capable to bind to the PON1 promoter. Clinical studies
conﬁrmed these in vitro ﬁndings, showing that during statin
treatmentserumPON1concentrationandactivityincreased.
Complementary studies of the same group revealed that
SREBP-2 binds to the PON1 promoter in an interactive
manner with Sp1 [36]. Another study presented evidence
that Sp1 acts as a positive regulator of PON1 transcription,
and that an interaction between Sp1 and protein kinase C
(PKC) is a key mechanism for the eﬀect of Sp1 on PON1
gene transcription [37]. The eﬀect of statins on PON1 gene
expression was further investigated using a reporter gene
assay by measuring luciferase activity of plasmids with a
PON1 promoter region transfected into human hepatomaJournal of Lipids 3
HepG2 cells [38]. Pitavastatin, simvastatin and atorvas-
tatin each signiﬁcantly increased PON1 promoter activity.
Transactivation by pitavastatin was completely abrogated
by mithramycin, an inhibitor of Sp1. More recently, the
same group of investigators demonstrated that pitavastatin
activates the transcription of PON1 gene via phosphoryla-
tion of SREBP-2 and stimulation of Sp1 binding to PON1
DNA through the activation of p44/42 MAP kinase signaling
cascade [39]. These eﬀects were mediated via PKC activation
[40]. Another class of hypolipidemic drugs are the bile acids
sequestrates, such as cholestyramine. Based on the ﬁndings
reported by Gutierrez et al. that bile acids repress PON1
mRNA expression via FXR activation of ileal FGF15 [41],
bile acids sequestrates may have beneﬁcial eﬀect on PON1
regulation.
High glucose was also shown to transactivate PON1 pro-
moter through Sp1 activation by PKC in cultured hepato-
cytes [42].
6. Polyphenols
Polyphenols constitute one of the largest category of
phytochemicals, most widely distributed among the plant
kingdom, and an integral part of the human diet. Dietary
consumption of some polyphenols present in wine [43]o r
in fruit juices increase serum PON1 activity in humans and
in mice [44–47]. The mechanisms of action of polyphenols
in the upregulation of PON1 were recently investigated
by several groups and these studies leaded to elucidation
of cellular signal transduction pathways and transcrip-
tion factors involved in hepatocyte PON1 gene regulation.
Quercetin is an ubiquitous ﬂavonoid present in all fruits
and vegetables. Dietary quercetin administration to rats was
shown to markedly upregulate hepatic PON1 expression at
the molecular level [48]. Other dietary polyphenols, such
as naringenin, catechin, and quercetin, increased PON1
gene expression by an aryl-hydrocarbon-receptor-(AhR-)
dependent mechanism [49]. Resveratrol, a polyphenolic
phytoalexin found in grapes and wine, increased PON1 gene
expression in human hepatocytes primary cultures and in
the HuH7 hepatocytes cell line, and this eﬀect involved a
transcriptional mechanism mediated by the unconventional
AhR responsive element in the PON1 gene promoter [50].
Berberine, a botanical alkaloid that has been isolated from
a number of medicinal plants, has major applications in
Chinese medicine. Treatment of HepG2 and HuH7 hepa-
tocytes with berberine increased PON1 expression at the
transcriptional level, via a JNK/c-Jun signaling pathway [51].
Pomegranatejuicecontainspolymolecularellagitannincom-
pounds, such as punicalagins, which are potent antioxidant
andantiatherogenicagents[52].Wehaverecentlyshownthat
pomegranate polyphenols mediated stimulation of PON1
gene expression in hepatocytes via cAMP-PKA signaling
cascade [53]. Based on previous analysis of the promoter
sequence of PON1 gene indicating that it could possibly be
regulated by nuclear receptors [35], we have expanded these
ﬁndings to elucidate a multisteps pathway of the proximal
signaling by which pomegranate juice polyphenols can
regulate PON1 gene transcription in hepatocytes. Our data
showthatPPARγ actsasthetranscriptionfactordownstream
of cAMP-PKA signaling cascade that upregulates PON1
gene transcriptional activity and increases PON1 mRNA
expression in hepatocytes [53, 54].
7. Urokinase-TypePlasminogen Activator
Direct evidence for PON1 being a target gene of PPARγ
evolved from studies investigating atherogenic roles of the
urokinase-type plasminogen activator (uPA). uPA is a serine
protease enzyme of the ﬁbrinolytic system, and uPA binding
to its receptor, uPAR, is implicated in plasmin generation
and also in nonproteolytic processes that extend beyond
its role in ﬁbrinolysis. We have recently shown that uPA
enhanced macrophage atherogenicity by increasing cellular
cholesterolaccumulation[55]andbypromotionofoxidative
stress [56]. Very recently we demonstrated that uPA reduces
hepatic PON1 gene transcription via its interaction with
uPAR on hepatocytes surface. Studies on the mechanism
responsible for this eﬀect showed that uPA binding to uPAR
stimulates MEK interaction with PPARγ in the nucleus,
leading to export of the nuclear PPARγ to the cytosol.
By using the chromatin immunoprecipitation (ChIP) assay
we have evidenced for the ﬁrst time that PPARγ binds to
DNA sequences in the PON1 promoter region and that
uPA reduces the association of PPARγ to PON1 promoter,
reducing thus PON1 gene transcription [57].
8. Conclusions and Perspectives
ThereisincreasingepidemiologicalevidencethatPON1pro-
tects against development of atherosclerosis. The emphasis
in this review was on nongenetic factors that modulate
molecular processes related to PON1 gene expression in
hepatocytes, reﬂecting PON1 level and activity in serum.
Research in this area has provided mechanistic insight into
how PON1 gene transcription can be increased by dietary
nutrients. However, as reviewed herein, many of the studies
use a single mechanistical approach in a speciﬁc model, and
thus progression to more pathophysiologically relevant in
vitro and animal models is essential. Understanding of these
molecular mechanisms is of fundamental importance for
atherosclerosis and cardiovascular disorders and could lead
to development of novel therapeutical avenues in treatment
of these diseases.
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